Characterization and Modulation of the Transferrin Receptor on Brain Capillary Endothelial Cells
Overview
Affiliations
Purpose: The expression level of the transferrin receptor (TfR) on brain capillary endothelial cells (BCECs) and the endocytosis of 125I-transferrin (125I-Tf) by this receptor was investigated. Furthermore, the influence of iron, the iron scavenger deferoxamine mesylate (DFO), astrocytic factors, a GTP-ase inhibitor (tyrphostin-A8, T8), lipopolysaccharide (LPS), and the radical scavenger N-acetyl-L-cysteine (NAC) on the TfR expression was studied to gain insight in the use and optimization of the TfR for drug targeting to the brain.
Methods: Experiments were performed with primary cultured bovine BCECs that were incubated with 125I-Tf at 4 degrees C (to determine binding) or at 37 degrees C (to determine endocytosis) in the absence or presence of the modulators. For full saturation curves in the absence or presence of iron or DFO, analysis was performed with a population approach using NONMEM, allowing us to estimate a single value for affinity (Kd, concentration of 50% receptor occupancy) and separate values for maximum receptor occupancy (B(max).
Results: On BCECs, the TfR is expressed extracellularly (B(max) of 0.13 fmol/microg cell protein), but also has a large intracellular pool (total B(max) of 1.37 fmol/microg cell protein), and is actively endocytosing Tf via clathrin-coated vesicles. At 4 degrees C, a Kd of 2.38 microg/ml was found, whereas the Kd at 37 degrees C was 5.03 microg/ml. Furthermore, DFO is able to increase both the extracellular as well as the total binding capacity to 0.63 and 3.67 fmol/microg cell protein, respectively, whereas it had no influence on Kd. B(max) at 37 degrees C after DFO preincubation was also increased from 0.90 to 2.31 fmol/microg cell protein. Other modulators had no significant influence on the TfR expression levels, though LPS increased cellular protein concentrations after 2-h preincubation.
Conclusions: The TfR is expressed on BCECs and actively endocytoses Tf, making it a suitable target for drug delivery to the bloodbrain barrier and the CNS. DFO up-regulates the TfR expression level, which may influence targeting efficiency.
Lim S, Yee G, Khang D Int J Nanomedicine. 2024; 19:2529-2552.
PMID: 38505170 PMC: 10949308. DOI: 10.2147/IJN.S450853.
Zhang W, Zhu D, Tong Z, Peng B, Cheng X, Esser L Pharmaceutics. 2023; 15(9).
PMID: 37765240 PMC: 10534822. DOI: 10.3390/pharmaceutics15092271.
Engineering antibody and protein therapeutics to cross the blood-brain barrier.
Zhao P, Zhang N, An Z Antib Ther. 2022; 5(4):311-331.
PMID: 36540309 PMC: 9759110. DOI: 10.1093/abt/tbac028.
Van Valkenburgh J, Meuret C, Martinez A, Kodancha V, Solomon V, Chen K Front Physiol. 2021; 12:700847.
PMID: 34552500 PMC: 8450374. DOI: 10.3389/fphys.2021.700847.
Dos Santos Rodrigues B, Kanekiyo T, Singh J Pharm Res. 2019; 36(11):161.
PMID: 31529284 PMC: 10150442. DOI: 10.1007/s11095-019-2691-7.